The potential role of fowlpox virus in rational vaccine design

Expert Review of Vaccines

Volumn 5, Issue 4, 2006, Pages 565-577

  Beukema, Emma L ^b,c   Brown, Michael P ^b,c,d   Hayball, John D ^a,b,c  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b HANSON INSTITUTE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Antigen presentation; Fowlpox virus; Immune evasion; Rational vaccine design; Viral tropism

Indexed keywords

ANTIGEN; CARCINOEMBRYONIC ANTIGEN PLUS TRIAD OF COSTIMULATORY MOLECULES; CYTOKINE; DNA VACCINE; FOWLPOX VIRUS PLUS TRIAD OF COSTIMULATORY MOLECULES; GRANZYME B; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MALARIA VACCINE; MONOCLONAL ANTIBODY; SERINE PROTEINASE INHIBITOR; SMALLPOX VACCINE; TGN 1412; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINE; VIRUS VACCINE;

ABSENCE OF SIDE EFFECTS; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; CANCER; CELLULAR IMMUNITY; CHORDOPOXVIRINAE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DEATH; DRUG EFFICACY; ENCEPHALITIS; FOWLPOX VIRUS; GENE DELETION; GENE EXPRESSION; GENOME; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSURVEILLANCE; IN VIVO STUDY; MALARIA; MAMMAL CELL; NONHUMAN; PERICARDITIS; POXVIRUS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; VACCINIA; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VECTOR;

AIDS VACCINES; APOPTOSIS; CANCER VACCINES; CLINICAL TRIALS; DRUG DESIGN; FOWLPOX VIRUS; HIV INFECTIONS; HUMANS; MALARIA; NEOPLASMS; POXVIRIDAE; SAFETY; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 33750304036     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.4.565     Document Type: Review

References (110)

1. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination and safety. Proc. Natl Acad. Sci. USA 93(21), 11341-11348 (1996).
2. Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nat. Med. 10(11), 1177-1185 (2004).
3. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 199, 227-250 (2004).
4. Doeuk DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell 124, 677-681 (2005).
5. Moss B. Poxviridae and their replication Fields BN, Kea DM (Eds), Raven Press, Ltd, NY, USA (1990). • Good introduction to the poxvirus family.
6. Smith SA, Kotwal GJ. Immune responses to poxvirus infections in various animals. Crit. Rev. Microbiol. 28(3), 149-185 (2002).
7. Boulanger D, Smith T, Skinner M. Morphogenesis and release of fowlpox virus. J. Gen. Virol. 81(3), 675-687 (2000).
8. Fenner F. Adventures with poxviruses of vertebrates. FEMS Microbiol. Rev. 24(2), 123-133 (2000).
9. Afonso CL, Tulman ER, Delhon G et al. Genome of crocodilepox virus. J. Virol. 80(10), 4978-4991 (2006).
10. Boulanger D, Green P, Jones B et al. Identification and characterisation of three immunodominant structural proteins of fowlpox virus. J. Virol. 76(19), 9844-9855 (2002).
11. Afonso CL, Tulman ER, Lu Z et al. The genome of fowlpox virus. J. Virol. 74(8), 3815-3831 (2000). • First full-length genome sequence of fowlpox virus (FPV).
12. Seet BT, Johnston JB, Brunetti CR et al. Poxviruses and immune evasion. Ann.Rev. Immunol. 21, 377-423 (2003). • Review of the wide range of immune evasion strategies employed by poxviruses.
13. Taylor J, Weinburg R, Languet B et al. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 6(6), 497-503 (1988). • First description of a recombinant FPV vaccine vector.
14. Singh P, Schnitzlein WM, Tripathy DN. Reticuloendotheliosis virus sequences within the genomes of field strains of fowlpox virus display variability. J. Virol. 77(10), 5855-5862 (2003).
15. Singh P, Kim T-J, Tripathy DN. Re-emerging fowlpox: evaluation of isolates from vaccinated flocks. Avian Pathol. 29, 449-455 (2000).
16. Hertig C, Coupar BE, Gould AR et al. Field and vaccine strains of fowlpox virus carry integrated sequences from the avian retrovirus, reticuloendotheliosis virus. Virology 235(2), 367-376 (1997).
17. Laidlaw SM, Skinner MA. Comparison of the genome sequence of FP9, an attenuated, tissue culture-adapted European strain of fowlpox virus, with those of virulent American and European viruses. J. Gen. Virol. 85(Pt 2), 305-322 (2004).
18. Webster DP, Dunachie S, McConkey S et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24(15), 3026-3034 (2006).
19. Skinner MA, Laidlaw SM, Eldaghayes I et al. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev. Vaccines 4(1), 63-76 (2005). • Review of the use of fowlpox virus (FPV) as a recombinant vaccine vector in mammals and poultry.
20. Brown M, Davies DH, Skinner MA et al. Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectors. Cancer Gene Ther. 6(3), 238-245 (1999). • Evidence that FPV is able to infect dendritic cells.
21. McFadden G. Poxvirus tropism. Nat. Rev. Microbiol. 3(3), 201-213 (2005). •• Key review of poxvirus tropism and host-range genes.
22. Kwak H, Horig H, Kaufman HL. Poxviruses as vectors for cancer immunotherapy. Curr. Opin. Drug Discov. Develop. 6(2), 161-168 (2003).
23. Somogyi P, Fraser J, Skinner MA. Fowlpox virus host range restriction: gene expression, DNA replication and morphogenesis in nonpermissive mammalian cells. Virology 197(1), 439-444 (1993). • Description of the ability of FPV to replicate in different mammalian cell types.
24. Chahroudi A, Chavan R, Kozyr N et al. Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor. J. Virol. 79(16), 10397-10407 (2005). •• First example of a host cellular receptor required for poxvirus entry.
25. Schneider-Schaulies J. Cellular receptors for viruses: links to tropism and pathogenesis. J. Gen. Virol. 81(Pt 6), 1413-1429 (2000).
26. Johnston JB, McFadden G. Poxvirus immunomodulatory strategies: current perspectives. J. Virol. 77(11), 6093-6100 (2003).
27. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Ann. Rev. Biochem. 68, 383-424 (1999).
28. Thornberry NA, Bull HG, Calaycay JR et al. A novel heterodimeric cysteine protease is required for interleukin-1 β processing in monocytes. Nature 356(6372), 768-774 (1992).
29. Zhou Q, Snipas S, Orth K et al. Target protease specificity of the viral serpin crmA. J. Biol. Chem. 272(12), 7797-7800 (1997).
30. Turner PC, Moyer RW. Control of apoptosis by poxviruses. Semin. Virol. 8(6), 453-469 (1998).
31. Alcami A, Symons J, Khanna A et al. Poxviruses: capturing cytokines and chemokines. Semin. Virol. 8(5), 419-427 (1998).
32. Puehler F, Schwartz H, Waidners B et al. An interferon-γ binding protein of novel structure encoded by the fowlpox virus. J. Biol. Chem. 278(9), 6905-6911 (2003).
33. Mossman K, Upton C, Buller RML et al. Specis specificity of ectromelia virus and vaccinia virus interferon-γ binding proteins. Virology 208(2), 762-769 (1995).
34. Gherardi MM, Ramirez JC, Esteban M. IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J. Gen. Virol. 84(8), 1961-1972 (2003).
35. Shtrichman R, Samuel CE. The role of γ interferon in antimicrobial immunity. Curr. Opin. Microbiol. 4(3), 251-259 (2001).
36. Wang F, Ma Y, Barrett JW et al. Disruption of erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat. Immunol. 5(12), 1266-1274 (2004).
37. Zinkernagel RM, Hengartner H. On immunity against infections and vaccines: credo 2004. Scand. J. Immunol. 60(1-2), 9-13 (2004).
38. Hutchings CL, Gilbert SC, Hill AV et al. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J. Immunol. 175(1), 599-606 (2005).
39. Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 21(4), 163-165 (2000).
40. Polo JM, Dubensky TW Jr. Virus-based vectors for human vaccine applications. Drug Discov. Today 7(13), 719-727 (2002).
41. Smith CL, Mirza F, Pasquetto V et al. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia ankara. J. Immunol. 175(12), 8431-8437 (2005).
42. Harrington LE, Most R Rv, Whitton JL et al. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J. Virol. 76(7), 3329-3337 (2002).
43. Ockenhouse CF, Sun PF, Lanar DE et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-PF7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177(6), 1664-1673 (1998).
44. Drexler I, Staib C, Kastenmuller W et al. Identification of vaccinia virus epitopespecific HLA-a*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc. Natl Acad. Sci. USA 100(1), 217-222 (2003).
45. + T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 201(1), 95-104 (2005).
46. Oseroff C, Kos F, Bui HH et al. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc. Natl Acad. Sci. USA 102(39), 13980-13985 (2005).
47. Slifka MK. The future of smallpox vaccination: is MVA the key? Med. Immunol. 4(1), 2 (2005).
48. Souza AP, Haut L, Reyes-Sandoval A et al. Recombinant viruses as vaccines against viral diseases. Braz. J. Med. Biol. Res. 38(4), 509-522 (2005).
49. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc. Natl Acad. Sci. USA 93(21), 11349-11353 (1996).
50. Coupar BEH, Teo T, Boyle DB. Restriction endonuclease mapping of the fowlpox virus genome. Virology 179(1), 159-167 (1990).
51. Robinson HL, Montefiori DC, Johnson RP et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 5(5), 526-534 (1999).
52. Kent SJ, Dale CJ, Ranasinghe C et al. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine 23(42), 5009-5021 (2005).
53. Letvin NL. Progress toward an HIV vaccine. Ann. Rev. Med. 56, 213-223 (2005).
54. + T cell response in mice using a fowlpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide. Viral Immunol. 15(2), 337-356 (2002).
55. Dale CJ, Zhao A, Jones SL et al. Induction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-γ. J. Med. Primatol. 29(3-4), 240-247 (2000).
56. Dale CJ, De Rose R, Stratov I et al. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. J. Virol. 78(24), 13819-13828 (2004).
57. Kent SJ Zhao A, Best SJ et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72(12), 10180-10188 (1998).
58. Moorthy VS, Imoukhuede EB, Keating S et al. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J. Infect. Dis. 189(12), 2213-2219 (2004).
59. Webster DP, Dunachie S, Vuola JM et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl Acad. Sci. USA 102(13), 4836-4841 (2005).
60. Yang S, Hodge JW, Grosenbach DW et al. Vaccines with enhanced costimulation maintain high avidity memory CTL. J. Immunol. 175(6), 3715-3723 (2005).
61. Marshall JL, Gulley JL, Arlen PM et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocytemacrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 23(4), 720-731 (2005).
62. Dipaola R, Plante M, Kaufman H et al. A Phase I trial of pox PSA vaccines (PROSTVAC(r)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOMtrade mark) in patients with prostate cancer. J. Transl. Med. 4, 1 (2006).
63. Kaufman HL, Wang W, Manola J et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern cooperative oncology group. J. Clin. Oncol. 22(11), 2122-2132 (2004).
64. Carroll MW, Moss B. Poxviruses as expression vectors. Curr. Opin. Biotechnol. 8(5), 573-577 (1997).
65. Taylor J, Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine 6(6), 466-468 (1988).
66. Bembridge GP, Lopez JA, Cook R et al. Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or γ interferon. J. Virol. 72(5), 4080-4087 (1998).
67. Zhu M, Terasawa H, Gulley J et al. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res. 61(9), 3725-3734 (2001).
68. Triozzi PL, Aldrich W, Allen KO et al. Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma. Int. J. Cancer. 113(3), 406-414 (2005).
69. Grosenbach DW, Barrientos JC, Schlom J et al. Synergy of vaccine strategies to amplify antigen-sepcific immune responses and antitumour effects. Cancer Res. 61(11), 4497-4505 (2001).
70. Hodge JW, Sabzevari H, Yafal AG et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59(22), 5800-5807 (1999).
71. Hodge JW, Rad AN, Grosenbach DW et al. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J. Natl Cancer Inst. 92(15), 1228-1239 (2000).
72. Marshall E. Drug trials. Violent reaction to monoclonal antibody therapy remains a mystery. Science 311(5768), 1688-1689 (2006).
73. Evans EJ, Esnouf RM, Manso-Sancho R et al. Crystal structure of a soluble CD28-FAb complex. Nat. Immunol. 6(3), 271-279 (2005).
74. Hopkin M. Can super-antibody drugs be tamed? Nature 440, 855-856 (2006).
75. + T cell responses: the alternative approaches. Ann. Rev. Immunol. 15, 297-322 (1997).
76. Reali E, Canter D, Zeytin H et al. Comparative studies of avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. Vaccine 23(22), 2909-2921 (2005).
77. Dale CJ, De Rose R, Wilson KM et al. Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN-γ or IL-12. Vaccine 23(2), 188-197 (2004).
78. Jackson RJ, Ramsay AJ, Christensen CD et al. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 75(3), 1205-1210 (2001).
79. Mullbacher A, Lobigs M. Creation of killer poxvirus could have been predicted. J. Virol. 75(18), 8353-8355 (2001).
80. Aung S, Graham B. IL-4 diminishes perforin-mediated and increases fas ligand-mediated cytotoxicity in vivo. J. Immunol. 164(7), 3487-3493 (2000).
81. + cytotoxic T lymphocyte population. Int. Immunol. 14(1), 31-37 (2002).
82. + T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J. Immunol. 172(5), 3094-3100 (2004).
83. Janeway CA, Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54(Pt 1), 1-13 (1989). • Original proposal describing how microbial pathogens are recognized by the innate immune system.
84. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124(4), 849-863 (2006).
85. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783-801 (2006).
86. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science 300(5625), 1524-1525 (2003).
87. Germain RN. An innately interesting decade of research in immunology. Nat. Med. 10(12), 1307-1320 (2004).
88. Napolitani G, Rinaldi A, Bertoni F et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6(8), 769-776 (2005).
89. + T cell responses in nonhuman primates. Proc. Natl Acad. Sci. USA 102(42), 15190-15194 (2005).
90. Wille-Reece U, Flynn BJ, Lore K et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203(5), 1249-1258 (2006).
91. Bowie A, Kiss-Toth E, Symons JA et al. A46R and A52R from vaccinia virus are antagonists of host IL-1 and Toll-like receptor signaling. Proc. Natl Acad. Sci. USA 97(18), 10162-10167 (2000).
92. Harte MT, Haga IR, Maloney G et al. The poxvirus protein A52R targets Tolllike receptor signaling complexes to suppress host defense. J. Exp. Med. 197(3), 343-351 (2003).
93. Pincus S, Tartaglia J, Paoletti E. Poxvirus-based vectors as vaccine candidates. Biologicals 23(2), 159-164 (1995).
94. Lanzavecchia A. From antigen presentation to T-cell activation. Res. Immunol. 149(7-8), 626 (1998).
95. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Ann. Rev. Immunol. 19, 47-64 (2001). • Good overview of the different antigen presentation pathways and the role of dendritic cells.
96. Ploegh HL. Immunology. Nothing 'gainst time's scythe can make defense. Science 304(5675), 1262-1263 (2004).
97. Heath WR, Belz GT, Behrens GM et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 199, 9-26 (2004).
98. Neijssen J, Herberts C, Drijfhout JW et al. Cross-presentation by intercellular peptide transfer through gap junctions. Nature 434(7029), 83-88 (2005).
99. Heath WR, Carbone FR. Coupling and cross-presentation. Nature 434(7029), 27-28 (2005).
100. Zinkernagel RM. On cross-priming of MHC class I-specific CTL: rule or exception? Eur. J. Immunol. 32(9), 2385-2392 (2002).
101. Hickman-Miller HD, Yewdell JW. Youth has its privileges: Maturation inhibits DC cross-priming. Nat. Immunol. 7(2), 125-126 (2006).
102. Wilson NS, Behrens GM, Lundie RJ et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 7(2), 165-172 (2006). •• Demonstrates that Toll-like receptor ligands can influence antigen presentation.
103. Sigal LJ, Crotty S, Andino R et al. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398(6722), 77-80 (1999).
104. + CTL following exposure to vaccinia virus via different routes. J. Immunol. 169(8), 4222-4229 (2002).
105. + T cells by infected dendritic cells in vivo. Nat. Immunol. 3(3), 265-271 (2002).
106. + T cell responses. Expert Opin. Biol. Ther. 4(6), 861-868 (2004). •• Discusses the importance of antigen presentation on vaccine efficacy.
107. + T cells in vivo: the key to rational vaccine design. Ann. Rev. Immunol. 23, 651-682 (2005). •• Review on the importance of antigen presentation for rational vaccine design.
108. HIV Vaccine Trials Network http://chi.ucsf.edu/vaccines/vaccines?page=vc- 02-00
109. Malaria Vaccine Trials www.malaria-vaccines.org.uk/5.shtml
110. US Federally Funded Clinal Trials www.clinical trials.gov.ct